Literature DB >> 28012901

Pravastatin and simvastatin inhibit the adhesion, replication and proliferation of Toxoplasma gondii (RH strain) in HeLa cells.

Raquel Arruda Sanfelice1, Suelen Santos da Silva1, Larissa Rodrigues Bosqui1, Milena Menegazzo Miranda-Sapla1, Bellisa Freitas Barbosa2, Rafaela José Silva2, Eloísa A Vieira Ferro2, Luciano Aparecido Panagio3, Italmar Teodorico Navarro4, Juliano Bordignon5, Ivete Conchon-Costa1, Wander Rogerio Pavanelli1, Ricardo Sergio Almeida3, Idessania Nazareth Costa6.   

Abstract

The conventional treatment for toxoplasmosis with pyrimethamine and sulfadiazine shows toxic effects to the host, and it is therefore necessary to search for new drugs. Some studies suggest the use of statins, which inhibit cholesterol synthesis in humans and also the initial processes of isoprenoid biosynthesis in the parasite. Thus, the objective of this study was to evaluate the activity of the statins pravastatin and simvastatin in HeLa cells infected in vitro with the RH strain of T. gondii. HeLa cells (1×105) were infected with T. gondii tachyzoites (5×105) following two different treatment protocols. In the first protocol, T. gondii tachyzoites were pretreated with pravastatin (50 and 100μg/mL) and simvastatin (1.56 and 3.125μg/mL) for 30min prior to infection. In the second, HeLa cells were first infected (5×105) with tachyzoites and subsequently treated with pravastatin and simvastatin for 24h at the concentrations noted above. Initially, we evaluated the cytotoxicity of drugs by the MTT assay, number of tachyzoites adhered to cells, number of infected cells, and viability of tachyzoites by trypan blue exclusion. The supernatant of the cell cultures was collected post-treatment for determination of the pattern of Th1/Th2/Th17 cytokines by cytometric bead array. There was no cytotoxicity to HeLa cells with 50 and 100μg/mL pravastatin and 1.56 and 3.125μg/mL simvastatin. There was no change in the viability of tachyzoites that received pretreatment. Regarding the pre- and post-treatment of the cells with pravastatin and simvastatin alone, there was a reduction in adhesion, invasion and proliferation of cells to T. gondii. As for the production of cytokines, we found that IL-6 and IL-17 were significantly reduced in cells infected with T. gondii and treated with pravastatin and simvastatin, when compared to control. Based on these results, we can infer that pravastatin and simvastatin alone possess antiproliferative effects on tachyzoites forms of T. gondii, giving these drugs new therapeutic uses.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HeLa cell; Statins; Toxoplasma gondii

Mesh:

Substances:

Year:  2016        PMID: 28012901     DOI: 10.1016/j.actatropica.2016.12.006

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  12 in total

1.  Endothelial dysfunction in acute acquired toxoplasmosis.

Authors:  Azhar H Al-Kuraishi; Salah D Al-Windy; Hayder M Al-Kuraishy; Ali I Al-Gareeb
Journal:  Trop Parasitol       Date:  2020-05-20

2.  Anti-Toxoplasma gondii Effects of a Novel Spider Peptide XYP1 In Vitro and In Vivo.

Authors:  Yuan Liu; Yaqin Tang; Xing Tang; Mengqi Wu; Shengjie Hou; Xiaohua Liu; Jing Li; Meichun Deng; Shuaiqin Huang; Liping Jiang
Journal:  Biomedicines       Date:  2021-08-01

3.  Interaction of apigenin-7-O-glucoside with pyrimethamine against Toxoplasma gondii growth.

Authors:  Daniel A Abugri; William H Witola
Journal:  J Parasit Dis       Date:  2019-12-02

4.  Modulation of host HIF-1α activity and the tryptophan pathway contributes to the anti-Toxoplasma gondii potential of nanoparticles.

Authors:  Oluyomi Stephen Adeyemi; Yuho Murata; Tatsuki Sugi; Yongmei Han; Kentaro Kato
Journal:  Biochem Biophys Rep       Date:  2017-07-05

5.  The Mechanism of Action of Ursolic Acid as a Potential Anti-Toxoplasmosis Agent, and Its Immunomodulatory Effects.

Authors:  Won Hyung Choi; In Ah Lee
Journal:  Pathogens       Date:  2019-05-09

6.  Rosuvastatin revert memory impairment and anxiogenic-like effect in mice infected with the chronic ME-49 strain of Toxoplasma gondii.

Authors:  Fernanda Ferreira Evangelista; Willian Costa-Ferreira; Francini Martini Mantelo; Lucimara Fátima Beletini; Amanda Hinobu de Souza; Priscilla de Laet Sant'Ana; Keller Karla de Lima; Carlos Cesar Crestani; Ana Lúcia Falavigna-Guilherme
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

7.  Efficient Cholesterol Transport in Dendritic Cells Defines Optimal Exogenous Antigen Presentation and Toxoplasma gondii Proliferation.

Authors:  Cristina Croce; Facundo Garrido; Sofía Dinamarca; Julien Santi-Rocca; Sabrina Marion; Nicolas Blanchard; Luis S Mayorga; Ignacio Cebrian
Journal:  Front Cell Dev Biol       Date:  2022-03-04

8.  Evaluation of Anti-Toxoplasma gondii Effect of Ursolic Acid as a Novel Toxoplasmosis Inhibitor.

Authors:  Won Hyung Choi; In Ah Lee
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-09

9.  Susceptibility of Toxoplasma gondii to Ethanolic Extract of Tinospora crispa in Vero Cells.

Authors:  Alhassan Abdullahi Sharif; Ngah Zasmy Unyah; Norshariza Nordin; Rusliza Basir; Mohammed Nasiru Wana; Ashraf Alapid Ahmad; Tijjani Mustapha; Roslaini Abd Majid
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-18       Impact factor: 2.629

Review 10.  Prenylquinones in Human Parasitic Protozoa: Biosynthesis, Physiological Functions, and Potential as Chemotherapeutic Targets.

Authors:  Ignasi B Verdaguer; Camila A Zafra; Marcell Crispim; Rodrigo A C Sussmann; Emília A Kimura; Alejandro M Katzin
Journal:  Molecules       Date:  2019-10-16       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.